Tiantan Biological approves investments, strategic asset sale

Beijing Tiantan Biological Products Corp. (Tiantan Biological) announced that its board of directors, at a meeting on November 28, 2025, approved several key resolutions. The board greenlighted the proposal for Tiantan Biological's subsidiary, Wuhan Zhongyuan Tiantan Biological Products Co., Ltd., to fully invest 10m yuan to increase the registered capital of Dangyang Tiantan Blood Plasma Collection Station Co., Ltd. to 20m yuan.

Additionally, Tiantan Biological's subsidiary will fully invest 7m yuan to increase the registered capital of Luotian Tiantan Blood Plasma Collection Station Co., Ltd. to 8m yuan. Both motions passed with unanimous approval.

The board also approved the public listing of 100% equity in Shanghai Shengwu Biological Products Co., Ltd., held by Sinopharm Group Shanghai Blood Products Co., Ltd., for no less than 15.50m yuan. This strategic divestment aims to facilitate state-owned asset management.

Furthermore, the board unanimously approved revisions to the "Rules of Procedure for the General Manager's Office Meeting," "Related Party Transaction Management System," and "Overall Risk Management Measures." All resolutions received full support from the nine participating directors.